SCHEDULE: JPMorgan Chase Discloses Stake in LB Pharmaceuticals

JPMorgan Chase & Co. has reported beneficial ownership of 5.2% of LB Pharmaceuticals Inc.'s common stock as of June 30, 2026.

Summary

• JPMorgan Chase & Co. has filed a Schedule 13G, indicating it beneficially owns 1,497,293 shares of LB Pharmaceuticals Inc. common stock.
• This ownership stake represents 5.2% of the class of securities.
• The filing date for this event is June 30, 2026.
• JPMorgan Chase & Co. has sole voting power over 1,379,375 shares and sole dispositive power over 1,497,293 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a major financial institution and does not inherently signal positive or negative performance for the company.

Positives

• JPMorgan Chase & Co. has a significant ownership stake, indicating confidence or strategic interest in LB Pharmaceuticals Inc.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding LB Pharmaceuticals Inc.'s future performance.

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common for publicly traded companies and provide transparency on significant stakes held by financial institutions. The 5.2% stake by JPMorgan Chase & Co. suggests a notable level of investment in LB Pharmaceuticals Inc.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal investor confidence, potentially influencing share price.
• Management: The filing provides transparency on significant ownership, which is a standard disclosure requirement.

Key Dates

Keywords

LB Pharmaceuticals Inc., JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Securities